Andy Minn

Andy Minn, Ph.D. is a professor in the Department of Radiation Oncology and an investigator in the Abramson Family Cancer Research Institute at the University of Pennsylvania. He is also director of the Mark Foundation Center for Immunotherapy, Immune Signaling and Radiation, and a project member in the Parker Institute for Cancer Immunotherapy. His research seeks to understand key mechanisms of cancer immunotherapy resistance. Specifically, his work focuses on the role of pattern recognition receptors and interferon signaling pathways, which are pathways that are typically activated when normal cells become infected with a virus. Surprisingly, cancers and many cancer therapies can also activate these pathways, prompting an interest in understanding how this happens, the impact on anti-tumor immunity and its clinical significance. An overarching goal is to translate this understanding to better inform the design of clinical trials. Dr. Minn’s work has been published in prestigious scientific journals such as Cell and Nature. He is also a member of the American Society for Clinical Investigators (ASCI). He received his M.D. and Ph.D. from the University of Chicago and finished his residency in radiation oncology along with his post-doctoral training at Memorial Sloan-Kettering Cancer Center.